An information infrastructure for the pharmaceutical market

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Health Services Research

Background:

• Joseph Newhouse's work highlights the inherent difficulties in establishing drug pricing policies that meet both economic efficiency and fairness criteria.
• The optimal allocation of pharmaceutical industry revenue between marketing and research & development (R&D) from a societal perspective remains unclear.
• Existing frameworks may not adequately address the social efficiency of pharmaceutical marketing and R&D expenditures.

Purpose of the Study:

• To investigate the societal efficiency of current pharmaceutical industry spending on marketing and R&D.
• To propose a novel approach for evaluating pharmaceutical cost-effectiveness.
• To advocate for an independent, publicly funded information infrastructure for disseminating such findings.

Main Methods:

• Literature review of existing drug pricing and R&D/marketing allocation studies.
• Conceptual framework development for assessing social efficiency in pharmaceutical spending.
• Proposal for establishing a public information infrastructure.

Main Results:

• Drug pricing policies face inherent trade-offs between economic efficiency and fairness.
• Current allocation of industry revenue to marketing and R&D may not be socially efficient.
• An independent information infrastructure is needed to objectively evaluate pharmaceutical cost-effectiveness.

Conclusions:

• Achieving both economic efficiency and fairness in drug pricing is exceptionally difficult.
• Further research is required to determine the socially optimal allocation of pharmaceutical industry resources.
• A publicly funded information infrastructure is essential for transparently assessing pharmaceutical value and guiding policy.